102 studies found for:    daclizumab
Show Display Options
Rank Status Study
1 Active, not recruiting Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: BIIB019 (Daclizumab HYP)
2 Completed Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Condition: Renal Transplantation
Interventions: Drug: Thymoglobulin (ATG);   Drug: Daclizumab
3 Completed
Has Results
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Conditions: Anterior Uveitis;   Arthritis, Juvenile Idiopathic;   Iritis;   Immunosuppression
Intervention: Drug: Daclizumab
4 Completed
Has Results
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Choroidal Neovascularization
Interventions: Drug: Intravenous Daclizumab;   Drug: Intravenous Infliximab;   Other: Observation;   Drug: Oral Rapamycin
5 Recruiting Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Conditions: Hodgkin Disease;   Hodgkin Lymphoma
Interventions: Radiation: 111In-daclizumab;   Radiation: 90Y-daclizumab
6 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
7 Completed A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Condition: Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Intervention: Drug: Daclizumab
8 Active, not recruiting Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Biological: Daclizumab High Yield Process (DAC HYP) (Active);   Drug: Interferon beta-1a Placebo;   Biological: Interferon beta-1a (IFN β-1a) (Active);   Drug: Daclizumab High Yield Process Placebo
9 Active, not recruiting An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BIIB019 (Daclizumab High Yield Process prefilled syringe);   Drug: Probe drug cocktail
10 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
11 Completed Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
Condition: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Intervention: Drug: CHOP-daclizumab
12 Completed Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
13 Completed Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
14 Completed To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Drug: Daclizumab;   Device: NB-UVB
15 Completed Daclizumab and Sirolimus to Treat Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
16 Completed Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
Condition: Non-Infectious Intermediate and Posterior Uveitis
Intervention: Drug: Daclizumab
17 Completed Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Condition: Graft vs Host Disease
Intervention: Drug: daclizumab, infliximab
18 Completed Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BIIB019 (Daclizumab High Yield Process);   Drug: Placebo
19 Completed ANTI-TAC THERAPY FOR UVEITIS
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
20 Completed MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
Condition: Kidney Transplantation
Intervention: Drug: daclizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years